Park JG, Park SY, Lee HW. Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy. World J Gastroenterol 2015; 21(8): 2568-2572 [PMID: 25741170 DOI: 10.3748/wjg.v21.i8.2568]
Corresponding Author of This Article
Soo Young Park, MD, PhD, Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Kyungpook National University, 130 Dongdeok-ro, Jung-gu, Daegu 700-721, South Korea. psyoung0419@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Feb 28, 2015; 21(8): 2568-2572 Published online Feb 28, 2015. doi: 10.3748/wjg.v21.i8.2568
Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy
Jung Gil Park, Soo Young Park, Hye Won Lee
Jung Gil Park, Division of Gastroenterology and Hepatology, Department of Internal Medicine, CHA University, Gumi CHA Medical Center, Gumi 730-728, South Korea
Soo Young Park, Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu 700-721, South Korea
Hye Won Lee, Department of Pathology, School of Medicine, Kyungpook National University, Daegu 700-721, South Korea
Author contributions: Park JG designed the report and collected the patient’s clinical data; Park SY performed the radiofrequency ablation; Lee HW analyzed histology and created histologic figure; Park JG and Park SY wrote the paper.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Soo Young Park, MD, PhD, Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Kyungpook National University, 130 Dongdeok-ro, Jung-gu, Daegu 700-721, South Korea. psyoung0419@gmail.com
Telephone: +82-53-2005519 Fax: +82-53-4268773
Received: September 14, 2014 Peer-review started: September 15, 2014 First decision: October 14, 2014 Revised: October 18, 2014 Accepted: November 11, 2014 Article in press: November 11, 2014 Published online: February 28, 2015 Processing time: 166 Days and 18.7 Hours
Abstract
Sorafenib, a potent multikinase inhibitor, lead to a significant improvement in progression free survival and overall survival in patients with advanced hepatocellular carcinoma (HCC). Though sorafenib has proven its efficacy in advanced stage HCC, there are limited reports on the role of sorafenib allowing for curative treatment by down-staging. We herein report a case of advanced HCC with vascular invasion, which showed treatment response by sorafenib therapy as to allow for radiofrequency ablation as curative treatment. The patient was followed-up for 6 mo without recurrence with continued sorafenib therapy.
Core tip: Though sorafenib is well known to efficacy in advanced hepatocellular carcinoma (HCC), the consensus of its role as down-staging is limited. Depending on response after sorafenib therapy, active strategy should be needed to offer chance for cure in advanced stage HCC.
